The earnings call reflects a strong positive outlook for Kiniksa Pharmaceuticals with significant revenue growth, increased sales guidance, and a robust financial position. The company highlights the increased adoption of ARCALYST and its FDA Orphan Drug Designation for KPL-387. However, challenges remain with limited market penetration and increased operating expenses.

Company Guidance

During the Kiniksa Pharmaceuticals third quarter 2025 earnings call, the company provided updated guidance, highlighting significant growth in ARCALYST revenue, which reached $180.9 million, representing a $24 million increase over the previous quarter and a $69 million increase compared to the third quarter of 2024. The company revised its full-year net sales guidance for ARCALYST, raising it to between $670 million and $675 million from a previous range of $625 million to $640 million. This adjustment reflects robust adoption and growth in the treatment of recurrent pericarditis, with the company noting a 61% year-over-year revenue growth. Kiniksa also emphasized its strong financial position, noting a net income of $18.4 million in Q3 2025 compared to a net loss of $12.7 million a year ago, and a cash balance increase of approximately $44 million to $352.1 million. The company remains focused on further penetrating the market, with current penetration at 15% in the multiple recurrence patient population, and on advancing its clinical portfolio, including the development of KPL-387, which received Orphan Drug Designation from the FDA for the treatment of pericarditis.

Significant Revenue Growth

ARCALYST revenue grew 61% year-over-year in the third quarter to $180.9 million.

Increased Guidance for ARCALYST Sales

Full year 2025 ARCALYST net sales guidance raised from $625 million-$640 million to $670 million-$675 million.

Orphan Drug Designation

FDA granted KPL-387 Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis.

Strong Financial Position

Net income of $18.4 million in Q3 2025 compared to a net loss of $12.7 million a year ago. Cash balance increased by approximately $44 million to $352.1 million.

Growing Prescriber Base

The number of prescribers increased by over 350 in Q3, leading to a total of more than 3,825 prescribers.

Kiniksa Pharmaceuticals (KNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 03, 2026	2025 (Q4)	0.41 / -	-0.12	―	―	―
Oct 28, 2025	2025 (Q3)	0.32 / 0.23	-0.18	227.78% (+0.41)
Jul 29, 2025	2025 (Q2)	0.22 / 0.23	-0.06	483.33% (+0.29)
Apr 29, 2025	2025 (Q1)	0.13 / 0.11	-0.25	144.00% (+0.36)
Feb 25, 2025	2024 (Q4)	0.02 / -0.12	0.35	-134.29% (-0.47)
Oct 29, 2024	2024 (Q3)	0.02 / -0.18	-0.2	10.00% (+0.02)
Jul 23, 2024	2024 (Q2)	-0.08 / -0.06	0.21	-128.57% (-0.27)
Apr 23, 2024	2024 (Q1)	-0.08 / -0.25	-0.18	-38.89% (-0.07)
Feb 28, 2024	2023 (Q4)	-0.10 / 0.35	0.06	483.33% (+0.29)
Oct 31, 2023	2023 (Q3)	-0.17 / -0.20	3.23	-106.19% (-3.43)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 28, 2025	$40.60	$39.43	-2.88%
Jul 29, 2025	$27.04	$30.37	+12.32%
Apr 29, 2025	$21.47	$25.88	+20.54%
Feb 25, 2025	$19.63	$19.72	+0.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kiniksa Pharmaceuticals (KNSA) report earnings?

Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on Mar 03, 2026, Before Open (Confirmed).

What is Kiniksa Pharmaceuticals (KNSA) earnings time?

Kiniksa Pharmaceuticals (KNSA) earnings time is at Mar 03, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KNSA EPS forecast?

KNSA EPS forecast for the fiscal quarter 2025 (Q4) is 0.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing